Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 154 entries
Sorted by: Best Match Show Resources per page
Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors.

Hepatic medicine : evidence and research

Gabrovska M, Geurs F, Ponette S, Ponette J, Bulte K, Derveaux L, Kempeneers I.
PMID: 24623997
Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009.

Few data are available on patient management in jaundice caused by liver metastases of solid tumors (nonbreast and noncolon origin). We report the first patient series consecutively treated with cisplatin weekly in patients with severe jaundice and liver failure...

Cite
Gabrovska M, Geurs F, Ponette S, et al. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009;1:9-12doi: 10.2147/hmer.s7574.
Gabrovska, M., Geurs, F., Ponette, S., Ponette, J., Bulte, K., Derveaux, L., & Kempeneers, I. (2009). Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepatic medicine : evidence and research, 19-12. https://doi.org/10.2147/hmer.s7574
Gabrovska, M, et al. "Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors." Hepatic medicine : evidence and research vol. 1 (2009): 9-12. doi: https://doi.org/10.2147/hmer.s7574
Gabrovska M, Geurs F, Ponette S, Ponette J, Bulte K, Derveaux L, Kempeneers I. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009. PMID: 24623997; PMCID: PMC3921826.
Copy Download .nbib Format: NLM
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?.

Hepatic medicine : evidence and research

Janardhan SV, Reau NS.
PMID: 25926761
Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015.

Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130-150 million people worldwide. The HCV treatment landscape has been transformed recently by the introduction of direct-acting antiviral (DAA) agents that target viral proteins,...

Cite
Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepat Med. 2015;7:11-20doi: 10.2147/HMER.S79584.
Janardhan, S. V., & Reau, N. S. (2015). Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepatic medicine : evidence and research, 711-20. https://doi.org/10.2147/HMER.S79584
Janardhan, Sujit V, and Reau, Nancy S. "Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?." Hepatic medicine : evidence and research vol. 7 (2015): 11-20. doi: https://doi.org/10.2147/HMER.S79584
Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015. PMID: 25926761; PMCID: PMC4403691.
Copy Download .nbib Format: NLM
Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease.

Hepatic medicine : evidence and research

Kawanaka M, Nishino K, Oka T, Urata N, Nakamura J, Suehiro M, Kawamoto H, Chiba Y, Yamada G.
PMID: 26082668
Hepat Med. 2015 Jun 03;7:29-35. doi: 10.2147/HMER.S79100. eCollection 2015.

OBJECTIVE: Amino acid imbalance is often found in patients with cirrhosis, and this imbalance is associated with insulin resistance. However, the mechanism underlying the relationship between amino acid imbalance and insulin resistance remains unclear. We evaluated serum amino acid...

Cite
Kawanaka M, Nishino K, Oka T, et al. Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepat Med. 2015;7:29-35doi: 10.2147/HMER.S79100.
Kawanaka, M., Nishino, K., Oka, T., Urata, N., Nakamura, J., Suehiro, M., Kawamoto, H., Chiba, Y., & Yamada, G. (2015). Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepatic medicine : evidence and research, 729-35. https://doi.org/10.2147/HMER.S79100
Kawanaka, Miwa, et al. "Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease." Hepatic medicine : evidence and research vol. 7 (2015): 29-35. doi: https://doi.org/10.2147/HMER.S79100
Kawanaka M, Nishino K, Oka T, Urata N, Nakamura J, Suehiro M, Kawamoto H, Chiba Y, Yamada G. Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepat Med. 2015 Jun 03;7:29-35. doi: 10.2147/HMER.S79100. eCollection 2015. PMID: 26082668; PMCID: PMC4461125.
Copy Download .nbib Format: NLM
Hepatitis C in Argentina: epidemiology and treatment.

Hepatic medicine : evidence and research

Gaite LA, Marciano S, Galdame OA, Gadano AC.
PMID: 24966701
Hepat Med. 2014 May 27;6:35-43. doi: 10.2147/HMER.S57774. eCollection 2014.

Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, where from 1.5% to 2.5% of adults are infected. Most of the infections were acquired 30-50 years ago. It is estimated that more than...

Cite
Gaite LA, Marciano S, Galdame OA, et al. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med. 2014;6:35-43doi: 10.2147/HMER.S57774.
Gaite, L. A., Marciano, S., Galdame, O. A., & Gadano, A. C. (2014). Hepatitis C in Argentina: epidemiology and treatment. Hepatic medicine : evidence and research, 635-43. https://doi.org/10.2147/HMER.S57774
Gaite, Luis Alejandro, et al. "Hepatitis C in Argentina: epidemiology and treatment." Hepatic medicine : evidence and research vol. 6 (2014): 35-43. doi: https://doi.org/10.2147/HMER.S57774
Gaite LA, Marciano S, Galdame OA, Gadano AC. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med. 2014 May 27;6:35-43. doi: 10.2147/HMER.S57774. eCollection 2014. PMID: 24966701; PMCID: PMC4043810.
Copy Download .nbib Format: NLM
Transmission, diagnosis, and management of hepatitis E: an update.

Hepatic medicine : evidence and research

Mirazo S, Ramos N, Mainardi V, Gerona S, Arbiza J.
PMID: 24966702
Hepat Med. 2014 Jun 03;6:45-59. doi: 10.2147/HMER.S63417. eCollection 2014.

Hepatitis E virus (HEV) infection is an important public health concern in many developing countries, causing waterborne outbreaks as well as sporadic autochthonous hepatitis. HEV is mainly transmitted by the fecal-oral route in endemic areas through drinking of contaminated...

Cite
Mirazo S, Ramos N, Mainardi V, et al. Transmission, diagnosis, and management of hepatitis E: an update. Hepat Med. 2014;6:45-59doi: 10.2147/HMER.S63417.
Mirazo, S., Ramos, N., Mainardi, V., Gerona, S., & Arbiza, J. (2014). Transmission, diagnosis, and management of hepatitis E: an update. Hepatic medicine : evidence and research, 645-59. https://doi.org/10.2147/HMER.S63417
Mirazo, Santiago, et al. "Transmission, diagnosis, and management of hepatitis E: an update." Hepatic medicine : evidence and research vol. 6 (2014): 45-59. doi: https://doi.org/10.2147/HMER.S63417
Mirazo S, Ramos N, Mainardi V, Gerona S, Arbiza J. Transmission, diagnosis, and management of hepatitis E: an update. Hepat Med. 2014 Jun 03;6:45-59. doi: 10.2147/HMER.S63417. eCollection 2014. PMID: 24966702; PMCID: PMC4051621.
Copy Download .nbib Format: NLM
Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response.

Hepatic medicine : evidence and research

Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T.
PMID: 26955295
Hepat Med. 2016 Feb 22;8:9-20. doi: 10.2147/HMER.S63700. eCollection 2016.

Autophagy is an intracellular lysosomal degradation process performed by the cells to maintain energy balance. The autophagy response plays an important role in the progression of liver disease due to hepatitis virus infection, alcoholic liver disease, nonalcoholic fatty liver...

Cite
Dash S, Chava S, Chandra PK, et al. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepat Med. 2016;8:9-20doi: 10.2147/HMER.S63700.
Dash, S., Chava, S., Chandra, P. K., Aydin, Y., Balart, L. A., & Wu, T. (2016). Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepatic medicine : evidence and research, 89-20. https://doi.org/10.2147/HMER.S63700
Dash, Srikanta, et al. "Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response." Hepatic medicine : evidence and research vol. 8 (2016): 9-20. doi: https://doi.org/10.2147/HMER.S63700
Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepat Med. 2016 Feb 22;8:9-20. doi: 10.2147/HMER.S63700. eCollection 2016. PMID: 26955295; PMCID: PMC4772942.
Copy Download .nbib Format: NLM
Challenging hepatitis C-infected liver transplant patients.

Hepatic medicine : evidence and research

Oliver M, Ortiz CC, Ortiz J.
PMID: 26889091
Hepat Med. 2016 Jan 18;8:1-8. doi: 10.2147/HMER.S96110. eCollection 2016.

Caring for liver transplant patients suffering from chronic hepatitis C virus (HCV) infection is a challenging task for transplant surgeons and primary physicians alike. HCV is the leading cause of liver transplantation in the USA and comes with a...

Cite
Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med. 2016;8:1-8doi: 10.2147/HMER.S96110.
Oliver, M., Ortiz, C. C., & Ortiz, J. (2016). Challenging hepatitis C-infected liver transplant patients. Hepatic medicine : evidence and research, 81-8. https://doi.org/10.2147/HMER.S96110
Oliver, Madeleine, et al. "Challenging hepatitis C-infected liver transplant patients." Hepatic medicine : evidence and research vol. 8 (2016): 1-8. doi: https://doi.org/10.2147/HMER.S96110
Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med. 2016 Jan 18;8:1-8. doi: 10.2147/HMER.S96110. eCollection 2016. PMID: 26889091; PMCID: PMC4723095.
Copy Download .nbib Format: NLM
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.

Hepatic medicine : evidence and research

Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M.
PMID: 26203290
Hepat Med. 2015 Jul 13;7:37-42. doi: 10.2147/HMER.S87594. eCollection 2015.

PURPOSE: Hepatic encephalopathy (HE) is a recurrent severe complication of progressive hepatic cirrhosis. The aim of this study is to evaluate the average annual direct healthcare costs for the treatment of patients with overt HE in Italy.PATIENTS AND METHODS:...

Cite
Roggeri DP, Roggeri A, Rossi E, et al. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015;7:37-42doi: 10.2147/HMER.S87594.
Roggeri, D. P., Roggeri, A., Rossi, E., Cinconze, E., Gasbarrini, A., Monici Preti, P., & De Rosa, M. (2015). Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepatic medicine : evidence and research, 737-42. https://doi.org/10.2147/HMER.S87594
Roggeri, Daniela Paola, et al. "Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs." Hepatic medicine : evidence and research vol. 7 (2015): 37-42. doi: https://doi.org/10.2147/HMER.S87594
Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015 Jul 13;7:37-42. doi: 10.2147/HMER.S87594. eCollection 2015. PMID: 26203290; PMCID: PMC4506032.
Copy Download .nbib Format: NLM
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?.

Hepatic medicine : evidence and research

Lim T.
PMID: 25506251
Hepat Med. 2014 Dec 03;6:113-8. doi: 10.2147/HMER.S60083. eCollection 2014.

Metabolic syndrome is prevalent in patients with hepatitis C virus (HCV) infection. Given the pandemic spread of HCV infection and metabolic syndrome, the burden of their interaction is a major public health issue. The presence of metabolic syndrome accelerates...

Cite
Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?. Hepat Med. 2014;6:113-8doi: 10.2147/HMER.S60083.
Lim, T. (2014). Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?. Hepatic medicine : evidence and research, 6113-8. https://doi.org/10.2147/HMER.S60083
Lim, Tr. "Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?." Hepatic medicine : evidence and research vol. 6 (2014): 113-8. doi: https://doi.org/10.2147/HMER.S60083
Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?. Hepat Med. 2014 Dec 03;6:113-8. doi: 10.2147/HMER.S60083. eCollection 2014. PMID: 25506251; PMCID: PMC4259863.
Copy Download .nbib Format: NLM
Hepatitis C in the Russian Federation: challenges and future directions.

Hepatic medicine : evidence and research

Mukomolov S, Trifonova G, Levakova I, Bolsun D, Krivanogova E.
PMID: 27217802
Hepat Med. 2016 May 05;8:51-60. doi: 10.2147/HMER.S50172. eCollection 2016.

Hepatitis C virus (HCV) infection is one of the most prevalent health problems in the world. Official registration of HCV infections in the Russian Federation started in 1994. Two clinical forms of infection - acute and chronic hepatitis C...

Cite
Mukomolov S, Trifonova G, Levakova I, et al. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med. 2016;8:51-60doi: 10.2147/HMER.S50172.
Mukomolov, S., Trifonova, G., Levakova, I., Bolsun, D., & Krivanogova, E. (2016). Hepatitis C in the Russian Federation: challenges and future directions. Hepatic medicine : evidence and research, 851-60. https://doi.org/10.2147/HMER.S50172
Mukomolov, Sergey, et al. "Hepatitis C in the Russian Federation: challenges and future directions." Hepatic medicine : evidence and research vol. 8 (2016): 51-60. doi: https://doi.org/10.2147/HMER.S50172
Mukomolov S, Trifonova G, Levakova I, Bolsun D, Krivanogova E. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med. 2016 May 05;8:51-60. doi: 10.2147/HMER.S50172. eCollection 2016. PMID: 27217802; PMCID: PMC4861609.
Copy Download .nbib Format: NLM
Autonomic dysfunction in chronic liver disease.

Hepatic medicine : evidence and research

Frith J, Newton JL.
PMID: 24367224
Hepat Med. 2011 Aug 23;3:81-7. doi: 10.2147/HMER.S16312.

It is becoming increasingly clear that quality of life (QOL) is impaired in those with chronic liver disease (CLD). One of the most important contributors to impaired QOL is the symptomatic burden which can range from slight to debilitating....

Cite
Frith J, Newton JL. Autonomic dysfunction in chronic liver disease. Hepat Med. 2011;3:81-7doi: 10.2147/HMER.S16312.
Frith, J., & Newton, J. L. (2011). Autonomic dysfunction in chronic liver disease. Hepatic medicine : evidence and research, 381-7. https://doi.org/10.2147/HMER.S16312
Frith, James, and Newton, Julia L. "Autonomic dysfunction in chronic liver disease." Hepatic medicine : evidence and research vol. 3 (2011): 81-7. doi: https://doi.org/10.2147/HMER.S16312
Frith J, Newton JL. Autonomic dysfunction in chronic liver disease. Hepat Med. 2011 Aug 23;3:81-7. doi: 10.2147/HMER.S16312. PMID: 24367224; PMCID: PMC3846459.
Copy Download .nbib Format: NLM
Update on new approaches in the management of hepatocellular carcinoma.

Hepatic medicine : evidence and research

Cabibbo G, Antonucci M, Genco C.
PMID: 24367214
Hepat Med. 2010 Nov 26;2:163-73. doi: 10.2147/HMER.S7132.

Hepatocellular carcinoma (HCC) is a major health problem. It is currently the third cause of cancer-related death, it is highly prevalent in the Asia-Pacific region and Africa, and is increasing in Western countries. The natural history of HCC is...

Cite
Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med. 2010;2:163-73doi: 10.2147/HMER.S7132.
Cabibbo, G., Antonucci, M., & Genco, C. (2010). Update on new approaches in the management of hepatocellular carcinoma. Hepatic medicine : evidence and research, 2163-73. https://doi.org/10.2147/HMER.S7132
Cabibbo, Giuseppe, et al. "Update on new approaches in the management of hepatocellular carcinoma." Hepatic medicine : evidence and research vol. 2 (2010): 163-73. doi: https://doi.org/10.2147/HMER.S7132
Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med. 2010 Nov 26;2:163-73. doi: 10.2147/HMER.S7132. PMID: 24367214; PMCID: PMC3846806.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 154 entries